Physicochemical characterisation and investigation of the bonding mechanisms of API-titanate nanotube composites as new drug carrier systems

Barbara Sipos, K. Pintye-Hódi, Z. Kónya, András Kelemen, Géza Regdon, Tamás Sovány

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Titanate nanotube (TNT) has recently been explored as a new carrier material for active pharmaceutical ingredients (API). The aim of the present work was to reveal the physicochemical properties of API-TNT composites, focusing on the interactions between the TNTs and the incorporated APIs. Drugs belonging to different Biopharmaceutical Classification System (BCS) classes were loaded into TNTs: diltiazem hydrochloride (BCS I.), diclofenac sodium (BCS II.), atenolol (BCS III.) and hydrochlorothiazide (BCS IV.). Experimental results demonstrated that it is feasible for spiral cross-sectioned titanate nanotubes to carry drugs and maintain their bioactivity. The structural properties of the composites were characterized by a range of analytical techniques, including FT-IR, DSC, TG–MS, etc. The interactions between APIs and TNTs were identified as electrostatic attractions, mainly dominated by hydrogen bonds. Based on the results, it can be stated that the strength of the association depends on the hydrogen donor strength of the API. The drug release of incorporated APIs was evaluated from compressed tablets and compared to that of pure APIs. Differences noticed in the dissolution profiles due to incorporation showed a correlation with the strength of interactions between the APIs and the TNTs observed in the above analytical studies.

Original languageEnglish
Pages (from-to)119-129
Number of pages11
JournalInternational Journal of Pharmaceutics
Volume518
Issue number1-2
DOIs
Publication statusPublished - Feb 25 2017

Fingerprint

Nanotubes
Drug Carriers
Trinitrotoluene
Pharmaceutical Preparations
Hydrogen
Hydrochlorothiazide
Atenolol
Diltiazem
Diclofenac
Static Electricity
Tablets

Keywords

  • Atenolol
  • Composite
  • Diclofenac sodium
  • Diltiazem hydrochloride
  • Hhydrochlorothiazide
  • Interaction
  • Titanate nanotube

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Physicochemical characterisation and investigation of the bonding mechanisms of API-titanate nanotube composites as new drug carrier systems. / Sipos, Barbara; Pintye-Hódi, K.; Kónya, Z.; Kelemen, András; Regdon, Géza; Sovány, Tamás.

In: International Journal of Pharmaceutics, Vol. 518, No. 1-2, 25.02.2017, p. 119-129.

Research output: Contribution to journalArticle

@article{3c725cd8f3d54449b5f7318665c42b6a,
title = "Physicochemical characterisation and investigation of the bonding mechanisms of API-titanate nanotube composites as new drug carrier systems",
abstract = "Titanate nanotube (TNT) has recently been explored as a new carrier material for active pharmaceutical ingredients (API). The aim of the present work was to reveal the physicochemical properties of API-TNT composites, focusing on the interactions between the TNTs and the incorporated APIs. Drugs belonging to different Biopharmaceutical Classification System (BCS) classes were loaded into TNTs: diltiazem hydrochloride (BCS I.), diclofenac sodium (BCS II.), atenolol (BCS III.) and hydrochlorothiazide (BCS IV.). Experimental results demonstrated that it is feasible for spiral cross-sectioned titanate nanotubes to carry drugs and maintain their bioactivity. The structural properties of the composites were characterized by a range of analytical techniques, including FT-IR, DSC, TG–MS, etc. The interactions between APIs and TNTs were identified as electrostatic attractions, mainly dominated by hydrogen bonds. Based on the results, it can be stated that the strength of the association depends on the hydrogen donor strength of the API. The drug release of incorporated APIs was evaluated from compressed tablets and compared to that of pure APIs. Differences noticed in the dissolution profiles due to incorporation showed a correlation with the strength of interactions between the APIs and the TNTs observed in the above analytical studies.",
keywords = "Atenolol, Composite, Diclofenac sodium, Diltiazem hydrochloride, Hhydrochlorothiazide, Interaction, Titanate nanotube",
author = "Barbara Sipos and K. Pintye-H{\'o}di and Z. K{\'o}nya and Andr{\'a}s Kelemen and G{\'e}za Regdon and Tam{\'a}s Sov{\'a}ny",
year = "2017",
month = "2",
day = "25",
doi = "10.1016/j.ijpharm.2016.12.053",
language = "English",
volume = "518",
pages = "119--129",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Physicochemical characterisation and investigation of the bonding mechanisms of API-titanate nanotube composites as new drug carrier systems

AU - Sipos, Barbara

AU - Pintye-Hódi, K.

AU - Kónya, Z.

AU - Kelemen, András

AU - Regdon, Géza

AU - Sovány, Tamás

PY - 2017/2/25

Y1 - 2017/2/25

N2 - Titanate nanotube (TNT) has recently been explored as a new carrier material for active pharmaceutical ingredients (API). The aim of the present work was to reveal the physicochemical properties of API-TNT composites, focusing on the interactions between the TNTs and the incorporated APIs. Drugs belonging to different Biopharmaceutical Classification System (BCS) classes were loaded into TNTs: diltiazem hydrochloride (BCS I.), diclofenac sodium (BCS II.), atenolol (BCS III.) and hydrochlorothiazide (BCS IV.). Experimental results demonstrated that it is feasible for spiral cross-sectioned titanate nanotubes to carry drugs and maintain their bioactivity. The structural properties of the composites were characterized by a range of analytical techniques, including FT-IR, DSC, TG–MS, etc. The interactions between APIs and TNTs were identified as electrostatic attractions, mainly dominated by hydrogen bonds. Based on the results, it can be stated that the strength of the association depends on the hydrogen donor strength of the API. The drug release of incorporated APIs was evaluated from compressed tablets and compared to that of pure APIs. Differences noticed in the dissolution profiles due to incorporation showed a correlation with the strength of interactions between the APIs and the TNTs observed in the above analytical studies.

AB - Titanate nanotube (TNT) has recently been explored as a new carrier material for active pharmaceutical ingredients (API). The aim of the present work was to reveal the physicochemical properties of API-TNT composites, focusing on the interactions between the TNTs and the incorporated APIs. Drugs belonging to different Biopharmaceutical Classification System (BCS) classes were loaded into TNTs: diltiazem hydrochloride (BCS I.), diclofenac sodium (BCS II.), atenolol (BCS III.) and hydrochlorothiazide (BCS IV.). Experimental results demonstrated that it is feasible for spiral cross-sectioned titanate nanotubes to carry drugs and maintain their bioactivity. The structural properties of the composites were characterized by a range of analytical techniques, including FT-IR, DSC, TG–MS, etc. The interactions between APIs and TNTs were identified as electrostatic attractions, mainly dominated by hydrogen bonds. Based on the results, it can be stated that the strength of the association depends on the hydrogen donor strength of the API. The drug release of incorporated APIs was evaluated from compressed tablets and compared to that of pure APIs. Differences noticed in the dissolution profiles due to incorporation showed a correlation with the strength of interactions between the APIs and the TNTs observed in the above analytical studies.

KW - Atenolol

KW - Composite

KW - Diclofenac sodium

KW - Diltiazem hydrochloride

KW - Hhydrochlorothiazide

KW - Interaction

KW - Titanate nanotube

UR - http://www.scopus.com/inward/record.url?scp=85007559024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007559024&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2016.12.053

DO - 10.1016/j.ijpharm.2016.12.053

M3 - Article

VL - 518

SP - 119

EP - 129

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -